NCT02387801View on ClinicalTrials.gov

A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

August 31, 2016

Conditions
Psoriasis
Interventions
DRUG

Ixekizumab

Administered SC

Trial Locations (1)

10029

Mount Sinai School of Medicine Dermatology Clinical Trials, New York

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02387801 - A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis | Biotech Hunter | Biotech Hunter